03 Jul Diabetes Medication Reduced Weight and Improved Metabolic Parameters in Obese Patients
Medical Research: What is the background for this study? What are the main findings?
Dr. Pi-Sunye: In a large randomized trial, the drug Liraglutide was compared to placebo in overweight and obese non-diabetic volunteers. Over 52 weeks, in combination with diet and increased physical activity, Liraglutide lowered body weight by 8.4 kg as compared to 2.8 kg in placebo. 63% vs 27% lost at least 5% of baseline weight, 33% vs 10% lost more than 10% of baseline weight.
Medical Research: What are the implications of this report?
Dr. Pi-Sunye: This medication adds to the armamentarium physicians will have in helping overweight and obese patients lose weight and maintain it off.
Medical Research: What is the take home message?
Dr. Pi-Sunye: Liraglutide can lower weight, improve cardiovascular risk factors and improve quality of life. It can also reduce the progression to type 2 diabetes from prediabetes.
Medical Research: What recommendations do you have for future research as a result of this study?
Dr. Pi-Sunye: I think it would be an advance if an oral analogue to this medication could be developed.
Xavier Pi-Sunyer, M.D., Arne Astrup, M.D., D.M.Sc., Ken Fujioka, M.D., Frank Greenway, M.D., Alfredo Halpern, M.D., Michel Krempf, M.D., Ph.D., David C.W. Lau, M.D., Ph.D., Carel W. le Roux, F.R.C.P., Ph.D., Rafael Violante Ortiz, M.D., Christine Bjørn Jensen, M.D., Ph.D., and John P.H. Wilding, D.M. for the SCALE Obesity and Prediabetes NN8022-1839 Study Group
Dr. F. Xavier Pi-Sunyer MD, & Division of Endocrinology and Obesity Research Center (2015). Diabetes Medication Reduced Weight and Improved Metabolic Parameters in Obese Patients